<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Therapy strategies for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e>) vary considerably </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To review the treatment of Brazilian children who were diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> in the past decade and reported to the Brazilian Cooperative Group on Pediatric <z:hpo ids='HP_0002863'>Myelodysplastic Syndromes</z:hpo> (BCG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-PED) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Of 173 children reported to the BCG-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-PED from January 1997 to January 2003 with a suspected diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e>, 91 had the diagnosis confirmed after central review of the bone marrow aspirate and biopsy </plain></SENT>
<SENT sid="3" pm="."><plain>Information on previous treatments was available for 78 MDS/JMML patients </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment varied from different schedules of low-dose (14%) and standard-dose chemotherapy (50%), granulocyte-colony-stimulating factor (G-CSF 7%), interferon (5%), steroids (2%) and erythropoietin (2%) to allogeneic stem-cell transplantation (SCT) (14%) </plain></SENT>
<SENT sid="5" pm="."><plain>No survival advantage could be demonstrated based on Hasle's classification or based on treatment </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: This report reflects the current practice in treating Brazilian children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> without specific Cooperative Group guidelines </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment modalities were very <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The strategies for implementing a national protocol should consider international guidelines and focus on local experience and available resources </plain></SENT>
</text></document>